Plain-English translation of NCT07054879 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →This trial is testing capecitabine as a maintenance medication—a treatment you would continue taking for a period after finishing your standard chemotherapy for pancreatic cancer. Researchers want to see if this additional medication helps prevent cancer from coming back and whether a special blood test can help doctors decide whether you need it.
Pancreatic cancer is aggressive and often comes back even after surgery and chemotherapy. Doctors want to know if continuing this medication longer might help keep you healthier and prevent recurrence.
You likely qualify if…
You likely don't qualify if…
You would first receive 6 cycles of standard chemotherapy (two medications given together). After that, you would take capecitabine as a maintenance medication based on how well you're doing. The study will also involve blood tests to check for cancer DNA, which may help your doctor decide if you need to continue the maintenance medication or can stop it.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
China
Enrollment target
~70 participants
Started
November 2024
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Juan Du, professor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.